A new frontier in patient engagement for chronic disease trials
A landmark study published in Alzheimer’s & Dementia demonstrates the feasibility and impact of large-scale, web-based patient and public involvement and engagement (PPIE) in clinical research. The study, involving over 3,250 participants across 27 countries, used an online portal to gather public preferences on treatment attributes and drug choices for a major adaptive platform trial testing repurposed drugs for Alzheimer’s disease. The analysis revealed that the probability of severe side effects was the most influential factor for participants when considering potential treatments, followed by the probability of mild side effects and the type of evidence supporting the drug. This scalable digital approach successfully captured diverse public perspectives to directly inform trial design and prioritization.
Why it might matter to you: This study provides a validated, scalable model for integrating patient values into complex clinical trial design, a methodology directly transferable to nephrology research. For professionals managing chronic kidney disease, where treatment adherence and patient-centered outcomes are paramount, applying this large-scale engagement framework could optimize trial protocols for dialysis modalities, immunosuppression regimens, or novel therapies for glomerular diseases. It underscores a strategic shift towards embedding quantitative patient preference data into the core development process for renal interventions.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
